In literature three histology-independent “basket” researches were reported, exploring the efficacy of Vemurafenib in BRAF V600E mutant non-melanoma cancers [18, 19], in which 2 SS (among 6 STS patients) with BRAF V600E mutation enrolled, and one report of 2 patients with SS expressing BRAF V600E mutation [20]. The gene discussed is BRAF; the disease is synovial sarcoma.